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Abstract
Background: Although rheumatoid arthritis has been shown to have moderately strong genetic
component, both linked loci identified in linkage analyses and susceptibility variants from
association studies are short of adequately accounting for a comprehensive catalogue of the
molecular factors underlying this complex disease. The objective of this study was to use
supplementary phenotype based on cumulative hazard of rheumatoid arthritis to identify linkage
evidence for new and additional rheumatoid arthritis loci in a genome-wide linkage analysis of 342
affected sibling pair families from the United Kingdom.
Methods: Using proportional hazards model, we estimated cumulative hazard of rheumatoid
arthritis and then used it as a quantitative trait in a non-parametric multipoint variance component
linkage analysis with 353 microsatellite markers distributed across the 22 autosomal chromosomes.
Results: We identified 3 new loci with genome-wide suggestive linkage evidence for rheumatoid
arthritis on 9q21.13, 15p11.1 and 20q13.33. Our results also confirmed previously reported linkage
evidence in the HLA-DRB1 region on chromosome 6 and on locus 1q32.1.
Conclusion: This study demonstrates the potential for information gain through the use of
supplementary phenotypes in genetic study of complex diseases to identify new and additional
potential linked loci that are not detected by linkage analysis of traditional phenotypes; and our
results provide further evidence of the involvement of multiple loci in the genetic aetiology of
rheumatoid arthritis.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory con-
dition that belongs to the family of diseases referred to as
autoimmune. The population prevalence of RA is about
0.01 [1,2], and the relative risk for siblings of affected per-
sons ranges between 2 and 17 [2-5]. In addition to evi-
dence from familial aggregation, results from twin studies
[6-8], segregation analysis [9] and genome-wide associa-
tion studies [10-12] all indicate evidence of genetic influ-
ence in the aetiology of RA. This evidence is further
strengthened by the relatively high heritability of RA, esti-
mated to be about 65% [13] from twin studies; and also
by reported linkage evidence for regions on chromosomes
2 and 11 [14], and 6 and 16 [15]. Although consistently
strong evidence across studies points to association with
the HLA locus on chromosome 6, it has however been
observed that the RA-HLA region association accounts for
only about one-third of the total genetic determinants of
susceptibility to RA [16,17]. On the other hand, none of
the other RA-linked loci reported to date has been consist-
ently reported across studies [1,3,14,18,19]. The implica-
tion is that it is likely that a number of other loci involved
in the genetic susceptibility to RA exist and are yet to be
identified and their individual roles quantified; hence the
complete role of genetic factor in the aetiology of this
complex disease remains to be clearly understood.
As with many other complex human diseases, the diffi-
culty in achieving a clear understanding of the role of
genetics in disease can partly be attributed to limitations
in phenotype definition and characterization. RA is a
complex disease condition with variation in onset age,
severity, and accompanying presence or absence of clini-
cal features such as nodules, erosions, and rheumatoid
factor. In addition, phenotypic, clinical and genetic heter-
ogeneity exists between studies. To address the problem of
heterogeneity associated with RA phenotype, John et al.
[15] and Eyre et al. [20] used stratified analyses based on
subgroups defined by age at disease onset, sex and clinical
features such as rheumatoid factor (RF) status, erosion
and shared epitopes. In addition to the affection status
variable, age at RA onset provides the opportunity to
investigate genetic influence based on the cumulative haz-
ard of RA by using survival analysis tool in combination
with linkage analysis. The premise is that detecting evi-
dence of linkage in regions not previously identified in
analysis of affection-based phenotype may be possible in
analysis of supplementary phenotype of the same disease.
The objective of this study was to use cumulative hazard
estimates from proportional hazards model in genome-
wide scan for linkage evidence for new and additional
genetic loci linked to RA using affected sibling pairs data.
We present here the results from the genome-wide linkage
analysis of the cumulative hazard to RA in a sample of 728
relatives from 342 affected sibling pair families from the
UK.
Methods
The RA affected sibling pair families used in this study
were part of the UK National Repository of Multicase
Rheumatoid Arthritis Families maintained by the Arthritis
Research Campaign (http://www.medicine.manches
ter.ac.uk/epidemiology/research/arc/). Details of family
recruitment and assessment protocols have been
described elsewhere [1,20]. Briefly, subjects were exam-
ined by trained metrologists using standardized question-
naires and protocols. Radiographs of each subject's hands
were reviewed and rheumatoid factor status of each sub-
ject was ascertained using a particle agglutination test. All
RA affected subjects satisfied the American College of
Rheumatology criteria [21,22]. Access to the UK RA data
was requested and approved through the Genetic Analysis
Workshop 15 (GAW15). The data used in the present
study were from cohorts 1 and 2 families as made availa-
ble through GAW15 [23]. Cohort 1 comprised of RA
affected sibling pairs from the 182 families as described by
Mackay et al [1] and cohort 2 was made up of RA affected
sibling pairs from the additional 195 families which have
been described elsewhere [20]. Available phenotypic and
clinical information included RA affection status, age at
onset of RA symptoms, erosion status, and RF status. Gen-
otype data on 353 informative microsatellite markers
from the ABI Prism Linkage Mapping set, spanning the 22
autosomes at an average inter-marker distance of 10 cM
were available on subjects and used in the present study.
Estimation of cumulative hazard
We restricted all analyses to RA affection status, age at
onset and sex since other measures such as severity of RA,
erosion status and RF status are measures of post-RA affec-
tion symptoms. Our objective was to study only those var-
iables that influence an individual's hazard to RA. Survival
analysis was performed using RA status, sex, and onset age
data on 750 affected subjects from 364 families. Since first
symptoms of RA can begin at any point in time, it is rea-
sonable to suppose that observed ties in event times (age
at onset) among subjects are likely results of approxima-
tion or convenience in measurement and that there is a
true but unknown ordering for the tied event times. This
supposition appears more plausible for event as onset of
RA and as such tied event times were treated according to
the method described by Kalbfleisch and Prentice [24],
and DeLong and colleagues [25]. Briefly, in the fitted pro-
portional hazards model, exact conditional probability
was computed for each event under the assumption that
all tied event times occur before censored times of the
same value or before larger values. The proportional haz-
ards model was based on the assumption that the hazard
to RA for any subject is a fixed proportion of the hazard to
RA for any other subject in the study sample and the ratios
of hazards are independent of time. The use of Cox regres-
sion to fit the proportional hazards model in this study
allowed us not to specify any particular distribution forBMC Medical Genetics 2009, 10:142 http://www.biomedcentral.com/1471-2350/10/142
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the underlying hazard function and also to test the
hypothesis of proportionality of hazards. We included sex
as a covariate and then modelled the survival function
from which the cumulative hazard for each subject was
estimated as the negative of the logarithm of the survival
function as -logS(t); where S(t) is the survival function at
time 't' estimated from the fitted proportional hazards
model.
Linkage analysis
For the linkage analysis, 22 families with singletons were
excluded because these were uninformative for linkage
analysis. The linkage analysis was therefore based on 342
families with a total of 728 affected siblings. There were
353 microsatellite markers across the 22 autosomal chro-
mosomes. For subjects not genotyped for some markers,
their genotypes were set to missing for such markers.
Allele frequencies for each marker were calculated using
maximum likelihood estimation method. The marker-
specific identity by descent (IBD) for sibling pairs within
each family, and the multipoint IBDs were computed
using the software SOLAR [26]. Since the estimated cumu-
lative hazard was on continuous scale, we therefore used
it as a quantitative trait in the linkage analysis as opposed
to a dichotomous trait that is used when RA is analysed as
affection status. The computed multipoint IBDs were used
in a nonparametric multipoint linkage analysis of the
cumulative hazard of RA using the software SOLAR. The
use of nonparametric linkage method enabled us not to
specify any inheritance model since the aetiology of RA is
complex. Linkage evidence was expressed as logarithm of
odds (LOD) scores for linkage at each chromosomal posi-
tion. LOD scores which were defined as the logarithm to
base 10 of likelihood ratio of the data assuming linkage
versus the analysis model assuming no linkage, were used
to summarize the evidence in favour of linkage and these
plotted by chromosome against the genetic marker posi-
tions.
Results
The distributions of pairs of RA affected siblings and sexes
in the total sample of 342 families included in the linkage
analysis are shown in Table 1. There were 306 families
with 2 affected siblings each, 31 families with 3 affected
siblings each, and 5 families with more than 3 affected
siblings each. The 728 subjects comprised of 537 females
and 191 males. Mean age in years at onset of RA is 41.6 for
the sample, 41.4 for females and 42.2 for males (P  =
0.8360) (Table 1). Influence of gender on RA hazard was
assessed by including sex as a covariate in the propor-
tional hazards model and then testing the null hypothesis
that its coefficient is not different from zero. We also
tested the hypothesis of proportionality of hazards in our
study sample. For both tests, we did not observe any sta-
tistical evidence against the null hypotheses of propor-
tionality of hazards and that of equality between zero and
coefficient of sex. The p-value for the coefficient of sex was
0.5109 and the p-value for the Kolmogorov-type supre-
mum test for proportional hazards assumption was
0.9640 based on 1000 bootstrap samples.
The distribution of the estimated cumulative hazard func-
tion is presented in Figure 1. The result shows a rather
slow rise in cumulative hazard from the early years up till
about age 42 years, which is also about the median sur-
vival time, and thereafter the cumulative hazard began to
accelerate more rapidly with increasing years. The strong-
est linkage evidence observed on each chromosome from
the results of the nonparametric multipoint linkage anal-
ysis using the 353 microsatellites markers are presented in
Table 2. Based on generally accepted thresholds of LOD
scores for genome-wide linkage studies [27], we observed
genome-wide significant evidence (LOD score ≥ 3.6; P ≤ 2
× 10-5) for linkage on chromosome 6. The linkage signal
spanned the HLA-DRB1 region (Figure 2) which has been
reported in other studies [1-3,14,18,28,29] to contain
potential RA loci. Other chromosomal regions with
genome-wide suggestive evidence for linkage (LOD score
≥ 2.2; P ≤ 7.4 × 10-4) were identified on chromosomes 1,
9, 15 and 20 and are displayed in Figure 3. The LOD score
of 3.3 on chromosome 20 at about 94 cM near the
D20S173 was the second highest followed by the LOD
score of 3.2 on chromosome 15 near the D15S994 marker
at about 41 cM. The signal on chromosome 1 was
observed in the region previously identified in other
reports [1,18,20,28-30], whereas those on chromosomes
Table 1: Distributions of affected sibling pair sizes
Size of sibling pair No. of families No. of subjects Mean onset age (years ± standard error)
23 0 6 6 1 2 -
33 1 9 3 -
43 1 2 -
51 5 -
61 6 -
All 342 728 41.63 ± 0.51
Females - 537 41.44 ± 0.61
Males - 191 42.17 ± 0.89BMC Medical Genetics 2009, 10:142 http://www.biomedcentral.com/1471-2350/10/142
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Table 2: Regions with highest LOD scores on each chromosome
Chromosome Locus LOD score Position (cM)‡ Nearest marker
1 1q32.1 3.2 235 D1S425
2 2q24.1 1.5 161 D2S142
3 3p26.3 1.0 8 D3S1297
4 4q34.1 2.0 173 D4S1539
5 5q15 1.3 105 D5S644
6 6p21.3 5.0 48 HLA-DRB1
7 7q36.2 0.5 181 D7S2465
8 8q21.3 1.3 38 D8S258
9 9q21.13 2.7 78 D9S167
10 10q25.1 1.6 132 D10S597
11 11q 0.1 86 D11S937
12 12q24.33 1.0 165 D12S1723
13 13q12.3 1.4 15 D13S217
14 14q13 0.6 57 D14S276
15 15p11.1 3.2 41 D15S994
16 16q13.13 1.9 20 D16S404
17 - 0.8 104 D17S1790
18 18q21.1 1.9 74 D18S474
19 19q13.2 1.5 66 D19S420
20 20q13.33 3.3 94 D20S173
21 - 0.0 - -
22 22q13.2 0.2 52 D22S274
‡cM: centiMorgan on Marshfield map
Distribution of cumulative hazard of rheumatoid arthritis Figure 1
Distribution of cumulative hazard of rheumatoid arthritis.BMC Medical Genetics 2009, 10:142 http://www.biomedcentral.com/1471-2350/10/142
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9, 15 and 20 have not previously been reported and thus
represent newly identified potential RA loci. The lengths
of the corresponding 1-LOD support intervals for the link-
age evidence on chromosomes 1, 6 and 15 were 22 cM, 31
cM and 26 cM, respectively. The location of the highest
linkage signal on chromosome 20 was near the end of the
chromosome thus making a reliable estimation of its sup-
port interval difficult. Genome-wide nominal linkage evi-
dence (LOD ≥ 0.8; P < 0.05) was identified on eleven
other chromosomal regions (Figure 4), some of these cor-
responded to previously reported regions with similar
level of linkage signal for RA [1,20,30].
Discussion
We report here genome-wide linkage evidence for RA
based on analysis of cumulative hazard estimated from
family data on RA affected sibling pairs. The objective of
the study was to identify additional evidence of linkage
for RA by using supplementary RA phenotype that we
envisioned would capture linkage information otherwise
undetected by the traditional affection-status phenotype
definition used in previous linkage studies of RA. The sup-
plementary phenotype approach was based on applica-
tion of proportional hazards modelling to estimate
cumulative hazard of RA based on affection status and RA
onset age for each study subject. 750 affected subjects
from 364 families were included in the estimation of
cumulative hazard using proportional hazards model.
The estimated cumulative hazard was then used as quan-
titative trait in linkage analysis of genotypes on 353 mic-
rosatellite markers spanning the 22 autosomes at an
average inter-marker distance of 10 cM.
In this study we have identified three new potential RA
loci which have not been reported or detected in previous
linkage analyses that used the traditional RA affection sta-
Region of significant genome-wide linkage evidence on chromosome 6 Figure 2
Region of significant genome-wide linkage evidence on chromosome 6.BMC Medical Genetics 2009, 10:142 http://www.biomedcentral.com/1471-2350/10/142
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tus. The new potential RA loci with strong genome-wide
suggestive linkage evidence are 9q21.13 with LOD score
of 2.7, 15p11.1 with LOD score of 3.2 and 20q13.33 with
LOD score of 3.3. In addition to the identified new poten-
tial RA loci, we also obtained linkage evidence in chromo-
somal regions that are consistent with previous findings.
The most significant genome-wide linkage evidence was
detected on chromosome 6 in the HLA-DRB1 region
which is consistent with previous reports [1-
3,14,18,28,29]. The genome-wide suggestive linkage evi-
dence detected in 1q32.1 is also similar to reported level
of linkage evidence in previous studies for the region [30].
Among the candidate genes located in locus 1q32.1 are
CHI3L1 (chitinase 3-like 1 (cartilage glycoprotein-39))
gene which has been implicated in local autoimmune
response that leads to chronic inflammation and joint
destruction in RA patients [31] and the IKBKE (inhibitor
of kappa light polypeptide gene enhancer in B-cells,
kinase epsilon) gene which has been reported to play a
role in synovial inflammation, extracellular matrix
destruction, and activation of the viral program and
innate immune response in RA [32]. Also, the HRH3 (his-
tamine receptor H3) gene located in locus 20q13.33, has
a role in neurogenic inflammation [33].
We note that in a previous linkage analysis of a subset of
these data (cohort 1 families), Mackay et al [1] reported
significant genome-wide evidence on chromosome 6 in
the same HLA-DRB1 region on which we have also
detected significant evidence, and also identified a region
on same chromosome with suggestive evidence plus 9
regions of nominal evidence on other chromosomes.
Likewise, in a slightly larger sample from the same UK
cohort 1 families, John et al [15] confirmed the linkage
evidence on chromosome 6 previously reported by
Mackay et al [1], but did not detect any suggestive linkage
evidence outside of chromosome 6. However, in another
linkage study involving both cohorts 1 and 2 families,
Eyre et al [20] failed to detect any significant or suggestive
linkage evidence. The fact that previously reported poten-
tial RA loci are replicated in the present study underscore
the validity of the supplementary RA phenotype approach
used here. The identification of new potential RA loci in
this study is a demonstration of the importance of the use
of supplementary phenotypes for genetic mapping of
complex diseases such as RA.
It is worth noting that in this study we did not include
clinical covariates such as rheumatoid factor status and
Chromosomal regions with suggestive linkage evidence Figure 3
Chromosomal regions with suggestive linkage evidence.BMC Medical Genetics 2009, 10:142 http://www.biomedcentral.com/1471-2350/10/142
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erosion status that were included in some of the previous
studies because these covariates measure symptoms
resulting from RA affection. It is therefore not illogical to
assume that an individual's cumulative hazard to RA
could not be influenced by such post-RA onset pheno-
types or clinical symptoms. We therefore chose not to
include in the model variables that we think do not influ-
ence an individual's hazard of being affected by RA.
Whether all the identified linkage regions in the present
study are true positives requires further studies. We
declare that the reproduction of linkage evidence at previ-
ously reported potential RA loci provides support for the
validity of the definition of supplementary RA phenotype
and modelling that we have used in the present study. We
recognise that supplementary phenotype as defined and
treated as quantitative trait in the present study may not
be practicable for every complex human disease pheno-
type. However, for complex diseases for which this
approach is applicable, this can lead to identification of
new additional genetic loci that could explain part of the
missing heritability [34] observed in susceptibility vari-
ants identified in association studies of complex diseases.
This supplementary phenotype approach can be used to
identify new candidate loci or narrow candidate regions in
linkage and association studies. It is envisioned that
results from both analyses of supplementary disease phe-
notypes and their corresponding traditional disease phe-
notype definitions would enhance the efficiency of the
"genetic dragnet" at capturing important genetic variants
contributing to complex diseases.
Conclusion
This present study demonstrates the potential informa-
tion gain through the use of supplementary phenotypes in
genetic study of complex diseases such as RA to detect new
and additional linked loci that are undetected in linkage
analysis of the traditional phenotypes. Also, our results
provide further evidence of the involvement of multiple
loci in the genetic aetiology of RA.
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